

August 10, 2018
BrightPath Biotherapeutics, Co., Ltd.

Announcement of Recognition of Extraordinary Loss (Impairment Loss)

Tokyo, August 10, 2018 — BrightPath Biotherapeutics Co., Ltd. (hereinafter, “the Company”) hereby announces the recognition of an extraordinary loss in the consolidated financial results for the first quarter (April 1, 2018 to June 30, 2018) of the fiscal year ending March 31, 2019 due to an impairment loss on noncurrent assets as detailed below.

1. Recognition of impairment loss on noncurrent assets

The Company examined noncurrent assets by comparing the amount of investment with the amount deemed recoverable through the investment period in accordance with the Accounting Standard for Impairment of Fixed Assets. As a result, the Company recorded an impairment loss of 182,818 thousand yen as an extraordinary loss.

2. Impact on business performance

The impact on the forecast of performance for the fiscal year ending March 31, 2019 is currently under review, and will be disclosed immediately if revisions are considered necessary including other factors, if any.

Contact

• BrightPath Biotherapeutics Co., Ltd.

Business Administration

Phone: +81-3-5840-7697

E-mail: irpr05@brightpathbio.com

<https://www.brightpathbio.com/english/index.html>